Role of asymmetric dimethylarginine in cardiovascular disease and diabetes

Biomarkers in Medicine

Volumn 2, Issue 4, 2008, Pages 317-320

  Schernthaner, Guntram ^a   Krzyzanowska, Katarzyna ^a  

^a KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BIOLOGICAL MARKER; DIMETHYLARGININASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; INSULIN; METFORMIN; THIOCTIC ACID;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE MARKER; EDITORIAL; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; METABOLIC REGULATION; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PULMONARY HYPERTENSION; RISK ASSESSMENT; RISK FACTOR;

EID: 54849408768     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/17520363.2.4.317     Document Type: Editorial

References (54)

1. Valiance P, Leone A, Calver A, Collier J, Moncada S: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339(8793), 572-575 (1992).
2. McBride AE, Silver PA: State of the arg: protein methylation at arginine comes of age. Cell 106(1), 5-8 (2001).
3. Ogawa T, Kimoto M, Sasaoka K: Purification and properties of a new enzyme, NG,NG-dimethylarginine dimethylaminohydrolase, from rat kidney. J. Biol. Chem. 264(17), 10205-10209 (1989).
4. Calver A, Collier J, Leone A, Moncada S, Vallance P: Effect of local intra-arterial asymmetric dimethylarginine (ADMA). on the forearm arteriolar bed of healthy volunteers. J. Hum. Hypertens. 7(2), 193-194 (1993).
5. Achan V, Broadhead M, Malaki M et al.: Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterlosder. Thromb. Vasc. Biol. 23(8), 1455-1459 (2003).
6. Zoccaii C, Bode-Böger S, Mallamaci F et al.: Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 358(9299), 2113-2117 (2001).
7. Böger RH, Bode-Böger SM, Thiele W, Junker W, Alexander K, Frïlich JC: Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 95(8), 2068-2074(1997).
8. Surdacki A, Nowicki M, Sandmann J et al.: Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J. Cardiovasc. Pharmacol. 33(4), 652-658 (1999).
9. Böger RH, Bode-Böger SM, Szuba A et al.: Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulatton 98(18), 1842-1847 (1998).
10. Stühlinger MC, Abbasi F, Chu JW et al.: Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 287(11), 1420-1426 (2002).
11. Abbasi F, Asagmi T, Cooke JP et al.: Plasma concentrations of asymmetric dimethylarginine are increased in patients with Type 2 diabetes mellitus. Am. J. Cardiol. 88(10), 1201-1203 (2001).
12. Tarnow L, Hovind P, Teerlink T, Stehouwer CD, Parving HH: Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in Type 1 diabetes. Diabetes Care 27(3), 765-769 (2004).
13. Krzyzanowska K, Mittermayer F, Krugluger W et al.: Asymmetric dimethylarginine is associated with macrovascular disease and total homocysteine in patients with Type 2 diabetes. Atherosclerosis 189(1), 236-240 (2006).
14. Krzyzanowska K, Mittermayer F, Shnawa N et al.: Asymmetrical dimethylarginine is related to renal function, chronic inflammation and macroangiopathy in patients with Type 2 diabetes and albuminuria. Diabet. Med. 24(1), 81-86 (2007).
15. Krzyzanowska K, Mittermayer F, Schnack C, Hofer M, Wolzt M, Schernthaner G: Circulating ADMA concentrations are elevated in hypopituitary adults with and without growth hormone deficiency. Eur. J. Clin. Invest. 35(3), 208-213 (2005).
16. Mittermayer F, Mayer BX, Meyer A et al.: Circulating concentrations of asymmetrical dimethyl-L-arginine am increased in women with previous gestational diabetes. Diabetologia 45(10), 1372-1378 (2002).
17. Schnabel R, Blankenberg S, Lubos E et al.: Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ. Res. 97(5), e53-e59 (2005).
18. Mittermayer F, Krzyzanowska K, Exner M et al.: Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced peripheral artery disease. Arterinscler. Thromb. Vasc. Biol. 26(11), 2536-2540 (2006).
19. Krzyzanowska, K, Mittermayer F, Woizt M, Schernthaner G: Asymmetric dimethylargirdne predicts cardiovascular events in patients with Type 2 diabetes. Diabetes Care 30(7), 1834-1839 (2007).
20. Lajer M, Tarnow L, Jorsal A, Teerlink T, Parving HH, Rossing P: Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in Type 1 diabetic patients with diabetic nephropathy. Diabetes Care 31(4), 747-752 (2008).
21. Duckelmann C, Mittermayer F, Halder DG, Altenberger J, Eichinger J, Wolzt M: Asymmetric dimethylarginine enhances cardiovascular risk prediction in patients with chronic heart failure. Arterioscler. Thromb. Vasc. Biol. 27(9), 2037-2042 (2007).
22. Skoro-Sajer N, Mittermayer F, Panzenboeck A et al.: Asymmetric dimethylarginine is increased in chronic thromboembolic pulmonary hypertension. Am. J. Respir. Crit. Care Med. 176(11), 1154-1160 (2007).
23. Suda O, Tkutsul M, Morishita T, et al. Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: involvement of renin-angiotensin system and oxidative stress. Arterloscier. Thromb. Vasc. Biol. 24(9), 1682-1688 (2004).
24. Tanaka M, Sydow K, Gunawan F et al.: Dimethylarginine dimethylaminohydrolase overexpression suppresses graft coronary artery disease. Circulation 112(11), 1549-1556(2005).
25. Matsumoto Y, Ueda S, Yamagishl S et al.: Dimethylarginine dimethylaminohydrolase prevents progression of renal dysfunction by inhibiting loss of peritubular capillaries and tubulointerstitial fibrosis in a rat model of chronic kidney disease. J. Am. Soc. Nephrol. 18(5), 1525-1533 (2007).
26. Konishi H, Sydow K, Cooke JP: Dimethylarginine dimethylaminohydrolase promotes endothelial repair after vascular injury. J. Am. Coll. Cardiol. 49(10), 1099-1105 (2007).
27. Mittermayer F, Pleiner I, Krzyzanowska K, Wiesinger GF, Francesconi M, Wolzt M: Regular physical exercise normalizes elevated asymmetrical dimethylarginine concentrations in patients with Type 1 diabetes mellitus. Wien. Klin. Wochenschr. 117(23-24), 816-820 (2005).
28. Richter B, Nlessner A, Penka M et al.: Endurance training reduces circulating asymmetric dimethylarginine and myeloperoxidase levels in persons at risk of coronary events. Thromb. Haemost. 94(6), 1306-1311 (2005).
29. Krzyzanowska K, Mittermayer F, Kopp HP, Wolzt M, Schernthaner G: Weight loss reduces circulating asymmetrical dimethylarginine concentrations in morbidly obese women. J. Clin. Endocrinol. Metab. 89(12), 6277-6281 (2004).
30. Yin QF, Xiong Y: Pravastatin restores DDAH-activity and endothelium-dependent relaxation of rat aorta after exposure to glycated protein. J. Cardiovasc. Pharmacol. 45(6), 525-532 (2005).
31. Scalera F, Martens-Lobenhoffer J, Bukowska A, Lendeckel U, Tager M, Bode-Boger SM: Effect of telmisartan on nitric oxide: asymmetrical dimethylarginine system: role of angiotensin II type 1 receptor-γ and peroxisome proliferator-activated receptor-γ signaling during endothelial aging. Hypertension 51(3), 696-703 (2008).
32. Wakino S, Hayashi K, Tatematsu S et al.: Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine demethylaminohydrolase in rats. Hypertens. Res. 28(3), 255-262 (2005).
33. Ching JW, Lee EK, Kim TH et al.: Effects of α-lipoic acid on the plasma levels of asymmetric dimethylarginine in diabetic end-stage renal disease patients on hemodialysis: a pilot study. Am. J. Nephrol. 27(1), 70-74 (2007).
34. Heutang D, Schulz H, Nickei I et al.: Asymmetrical dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment. J. Clin. Endocrinol. Metab. 93(1), 82-90 (2008).
35. Asagami T, Abbasi F, Stuelinger M et al.: Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with Type 2 diabetes. Metabolism 51(7), 843-846 (2002).
36. Chen JW, Hsu NW, Wu TC, Lin SJ, Chang MS. Long-term angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X. Am. J. Cardiol. 90(9), 974-982 (2002).
37. Napoli C, Sica V, de Nigris F et al.: Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide ppthway in patients with essential hypertension. Am. Heart J. 148(1), e5 (2004).
38. Ito A, Egashira K, Narishige T, Muramatsu K, Takeshita A: Renin-angiotensin system is involved in the mechanbm of increased serum asymmetric dimethylarginine in essential hypertension. Jpn Circ. J. 65(9), 775-778 (2001).
39. Kawata T, Daimon M, Hasegawa R et al.: Effect of anglotensin-converting enzyme inhibitor on serum asymmetric dimethylarginine and coronary circulation in patients with Type 2 diabetes mellitus. Int. J. Cardiol. (2007) (Epub ahead of print).
40. Lin KY, Ito A, Asagami T et al.: Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 106(8), 987-992 (2002).
41. Palva H, Laakso J, Lehtimaki T, Isomustajarvi M, Ruokonen I, Laaksonen R: Effect of high-dose statin treatment on plasma concentrations of endogenous nitric oxide synthase inhibitors. J. Cardiovasc. Pharmacol. 41(2), 219-222 (2003).
42. Valkonen VP, Laakso J, Paiva H et al.: Asymmetrical dimethylarginine (ADMA) and risk of acute coronary events. Does statin treatment influence plasma ADMA levels? Atheroscler. Suppl. 4(4), 19-22 (2003).
43. Shinohara K, Shoji T, Kimoto E et al.: Effect of atorvastatin on regional arterial stiffness in patients with Type 2 diabetes mellitus. J. Atheroscler. Thromb. 12 (4), 205-210 (2005).
44. Eid HM, Eritsland J, Larsen J, Arnesen H, Seljeflot I: Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. Effects of pravastatin. Atherosclerosis 166(2), 279-284 (2003).
45. Pereira EC, Bertolami MC, Faludi AA, Salem M, Bersch D, Abdalla DS: Effects of simvastatin and L-arginine on vasodilation, nitric oxide metabolites and endogenous NOS inhibitors in hypercholesterolemic subjects. Free Radic. Res. 37(5), 529-536 (2003).
46. Lu TM, Ding YA, Leu HB, Yin WH, Sheu WH, Chu KM: Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. Am. J. Cardiol. 94(2), 157-161 (2004).
47. Kelly AS, Thelen AM, Kaiser DR, Gonzalez-Campoy JM, Bank AJ: Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with Type 2 diabetes mellitus. Vasc. Med. 12(4), 311-318 (2007).
48. Worthley MI, Holmes AS, Willoughby SR et al.: The deleterious effects of hyperglycemia on platelet function in diabetic patients with acute coronary syndromes mediation by superoxide production, resolution with intensive insulin administration. J. Am. Coll. Cardiol. 49(3), 304-310 (2007).
49. Yasuda S, Miyazaki S, Kanda M et al.: Intensive treatment of risk factors in patients with Type-2 diabetes mellitus is associated with improvement of endothelial function coupled with a reduction in the levels of plasma asymmetric dimethylarginine and endogenous inhibitor of nitric oxide synthase. Eur. Heart J. 27(10), 1159-1165 (2006).
50. Anderson JL, Carlquist JF, Roberts WL et al.: Asymmetric dimethylarginine, cortisol/cortisone ratio, and C-peptide: markers for diabetes and cardiovascular risk? Am. Heart J. 153(1), 67-73 (2007).
51. Mittermayer F, Kautzky-Willer A, Winzer C et al.: Elevated concentrations of asymmetric dimethylarginine are associated with deterioration of glucose tolerance in women with previous gestational diabetes mellitus. J. Intern. Med. 261(4), 392-398 (2007).
52. Ravani P, Tripepi G, Malberti F, Testa S, Mallamaci F, Zoccali C: Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J. Am. Soc. Nephrol. 16(8), 2449-2455(2005).
53. Ueda S, Yamagishi S, Matsumoto Y, Fukami K, Okuda S: Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease. Clin. Exp. Nephrol. 11(2), 115-121 (2007).
54. Malecki MT, Undas A, Cyganek K et al.: Plasma asymmetric dimethylarginine (ADMA) is associated with retinopathy in Type 2 diabetes. Diabetes Care 30(11), 2899-2901 (2007).